Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Melanoma (2)
- Attendance (1)
- Attrition (1)
- BRAF (1)
- COPD (1)
-
- Cardiology (1)
- Cardiovascular imaging (1)
- Chronic obstructive pulmonary disease (1)
- Circulating tumour DNA (ctDNA) (1)
- Completion (1)
- Immune Checkpoint Inhibitors (1)
- Immunotherapy (1)
- Inclinometer (1)
- Maintenance (1)
- Meta-analysis (1)
- Neoantigen load (1)
- Oncology (1)
- Pulmonary rehabilitation (1)
- Radiotherapy (1)
- Response (1)
- Sedentary time (1)
- Skin Neoplasms (1)
- Systematic review (1)
- Targeted therapy (1)
- Tumour mutational burden (1)
- Uptake (1)
- [RSTDPub] (1)
Articles 1 - 5 of 5
Full-Text Articles in Diseases
Pembrolizumab Versus Placebo As Adjuvant Therapy In Resected Stage Iib Or Iic Melanoma: Outcomes In Histopathologic Subgroups From The Randomized, Double-Blind, Phase 3 Keynote-716 Trial, Dirk Schadendorf, Jason J. Luke, Paolo A. Ascierto, Georgina V. Long, Piotr Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis De La Cruz-Merino, Jacek Mackiewicz, Vanna C. Sileni, John M. Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S. Carlino, Yujie Zhao, Mizuho Kalabis, Clemens Krepler, Alexander Eggermont, Richard A. Scolyer
Pembrolizumab Versus Placebo As Adjuvant Therapy In Resected Stage Iib Or Iic Melanoma: Outcomes In Histopathologic Subgroups From The Randomized, Double-Blind, Phase 3 Keynote-716 Trial, Dirk Schadendorf, Jason J. Luke, Paolo A. Ascierto, Georgina V. Long, Piotr Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis De La Cruz-Merino, Jacek Mackiewicz, Vanna C. Sileni, John M. Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S. Carlino, Yujie Zhao, Mizuho Kalabis, Clemens Krepler, Alexander Eggermont, Richard A. Scolyer
Research outputs 2022 to 2026
Background Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) versus placebo in the phase 3 KEYNOTE-716 study of resected stage IIB or IIC melanoma. At the prespecified third interim analysis (data cut-off, January 4, 2022), the HR for RFS in the overall population was 0.64 (95% CI, 0.50 to 0.84) and the HR for DMFS was 0.64 (95% CI, 0.47 to 0.88). We present a post hoc analysis of efficacy by subtypes defined by histopathologic characteristics. Methods Patients aged ≥ 12 years with newly diagnosed, resected stage IIB or IIC melanoma were randomly assigned (1:1) to …
Quantifying Uptake And Completion Of Pulmonary Rehabilitation Programs In People With Chronic Obstructive Pulmonary Disease Known To Tertiary Care, Sarah Hug, Vinicius Cavalheri, Daniel F. Gucciardi, Kylie Hill
Quantifying Uptake And Completion Of Pulmonary Rehabilitation Programs In People With Chronic Obstructive Pulmonary Disease Known To Tertiary Care, Sarah Hug, Vinicius Cavalheri, Daniel F. Gucciardi, Kylie Hill
Research outputs 2022 to 2026
Background: People with symptomatic chronic obstructive pulmonary disease (COPD) benefit from pulmonary rehabilitation programs (PRPs), but program attrition is common. Methods: For people with COPD who presented to tertiary care and appeared appropriate for a PRP, we prospectively mapped their PRP journey, explored factors influencing attendance to pre-program assessment and captured program attrition. Results: Of the 391 participants, 31% (95% CI 27 to 36) were referred to a PRP (n = 123; age 68 ± 10years, 62 males [50%], FEV1 45 ± 19%predicted). Of those referred, 94 (76% [69 to 84]) attended a pre-program assessment. Ex-smokers and those who had …
Protocol: Can Coronary Artery Calcium Score Identified On Thoracic Planning Ct Scans Be Used And Actioned To Identify Cancer Survivors At High Risk Of Cardiac Events: A Feasibility Study In Cancer Survivors Undergoing Radiotherapy In Australia, Jack Dalla Via, Nina Stewart, Mary A. Kennedy, Daniel A. Cehic, Peter Purnell, Joanne Toohey, Jamie Morton, Sabashini K. Ramchand, Joshua R. Lewis, Yvonne Zissiadis
Protocol: Can Coronary Artery Calcium Score Identified On Thoracic Planning Ct Scans Be Used And Actioned To Identify Cancer Survivors At High Risk Of Cardiac Events: A Feasibility Study In Cancer Survivors Undergoing Radiotherapy In Australia, Jack Dalla Via, Nina Stewart, Mary A. Kennedy, Daniel A. Cehic, Peter Purnell, Joanne Toohey, Jamie Morton, Sabashini K. Ramchand, Joshua R. Lewis, Yvonne Zissiadis
Research outputs 2022 to 2026
INTRODUCTION: A coronary artery calcium (CAC) CT scan can identify calcified plaque and predict risk of future cardiac events. Cancer survivors undergoing thoracic radiotherapy routinely undergo a planning CT scan, which presents a unique opportunity to use already obtained medical imaging to identify those at the highest risk of cardiac events. While radiation therapy is an important modality for many cancer treatments, radiation dose to the heart in thoracic radiotherapy leads to cardiotoxicity and may accelerate pre-existing atherosclerosis. The primary aims of this study are to investigate the feasibility of using CAC scores calculated on thoracic radiotherapy planning CT scans …
Quantifying The Effect Of Monitor Wear Time And Monitor Type On The Estimate Of Sedentary Time In People With Copd: Systematic Review And Meta-Analysis, Fiona Coll, Vinicius Cavalheri, Daniel F. Gucciardi, Sheldon Wulff, Kylie Hill
Quantifying The Effect Of Monitor Wear Time And Monitor Type On The Estimate Of Sedentary Time In People With Copd: Systematic Review And Meta-Analysis, Fiona Coll, Vinicius Cavalheri, Daniel F. Gucciardi, Sheldon Wulff, Kylie Hill
Research outputs 2022 to 2026
In studies that have reported device-based measures of sedentary time (ST) in people with chronic obstructive pulmonary disease (COPD), we explored if the monitor type and monitor wear time moderated the estimate of this measure. Five electronic databases were searched in January 2021. Studies were included if >70% of participants had stable COPD, and measures of ST (min/day) were collected using wearable technology. Meta-regression was used to examine the influence of moderators on ST, monitor type, and wear time. The studies identified were a total of 1153, and 36 had usable data for meta-analyses. The overall pooled estimate of ST …
The Prognostic Impact Of Circulating Tumour Dna In Melanoma Patients Treated With Systemic Therapies—Beyond Braf Mutant Detection, Gabriela Marsavela, Peter A. Johansson, Michelle R. Pereira, Ashleigh C. Mcevoy, Anna L. Reid, Cleo Robinson, Lydia Warburton, Muhammad A. Khattak, Tarek M. Meniawy, Benhur Amanuel, Michael Millward, Nicholas K. Hayward, Melanie R. Ziman, Elin S. Gray, Leslie Calapre
The Prognostic Impact Of Circulating Tumour Dna In Melanoma Patients Treated With Systemic Therapies—Beyond Braf Mutant Detection, Gabriela Marsavela, Peter A. Johansson, Michelle R. Pereira, Ashleigh C. Mcevoy, Anna L. Reid, Cleo Robinson, Lydia Warburton, Muhammad A. Khattak, Tarek M. Meniawy, Benhur Amanuel, Michael Millward, Nicholas K. Hayward, Melanie R. Ziman, Elin S. Gray, Leslie Calapre
Research outputs 2014 to 2021
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. In this study, we evaluated the predictive value of circulating tumour DNA (ctDNA) to inform therapeutic outcomes in metastatic melanoma patients receiving systemic therapies. We analysed 142 plasma samples from metastatic melanoma patients prior to commencement of systemic therapy: 70 were treated with BRAF/MEK inhibitors and 72 with immunotherapies. Patient-specific droplet digital polymerase chain reaction assays were designed for ctDNA detection. Plasma ctDNA was detected in 56% of patients prior to first-line anti-PD1 and/or anti-CTLA-4 treatment. The detection rate in the immunotherapy cohort was comparably lower than those with BRAF inhibitors …